1Jennings PL. Vascular benefits of gliclazide beyond glycemic control[J]. Metabolism,2000,49(10 Suppl2):17-20
2Wasada T. Adenosine triphopsphate-sensitive potassium(K(ATP))channel activity is coupled with insulin resistance in obesity and type 2 diabetes mellitus[J].Intern Med,2002,41(2):84-90
3Juhl CB, Porksen N, Pincus SM,et al. Acute and short-term administration of a sulfonylurea (Gliclazide) increases pulsatile insulin secretion in type 2 diabetes[J]. Diabetes,2001,50:1778-1783
4Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes[J]. The Lancet,2003,362:1275-1281
6Proks P, Reimann F, Green N, et al. Sulfonylurca stimulation of insulin secretion[J]. Diabetes,2002,51(Suppl 3):S368-S376
7Rodreguez E, Pulido N, Romero R, et al. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle[J]. Endocrinology,2004,145(2): 679-685
8Fava d, Cassone-Fakdetta M, Laurenti O, et al. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes[J]. Diabet Med,2002,19(9): 752-757
9McGavin JK, Perry CM, Goa KL. Gliclazide modified release[J]. Drugs,2002, 62(9):1357-1364
10Gust C. Gliclazide modified release[J]. Drug,2002,62(9); 1365-1366
6American Diabetes Association. Report of the expert committee on the expert committee on the diagnosis and classitication of diabetes mellitus care, 1997,20 : 1183-1186.
8American Diabetes Association. Report of the expert committee on the expert committee on the diagnosis and classitication of diabetes mellitus Care 1997; 20:1183 - 1186.
9American Diabetes Association. Standards of medical care of patients with diabetes mellitus ( Position Statement). Diabetes Care 1999;22(Suppl 1) :s32.
10Guillausseau PJ. Compliance and optimization of oral antidiabetie therapy: a longitudial study. Presse Med, 2004, 33: 156-160.
